## Listing of Claims

- 1 to 120. (Canceled).
- 121. (Amended) A solid formulation eemprising consisting of 40 % w/w of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate, 47.5 % w/w mannitol, 6 % w/w croscarmellose sodium, 5 % w/w povidone and 1.5 % w/w magnesium stearate.

122 to 123. (Canceled)

- 124. (Amended) The desage form of claim 123 A dosage form consisting of the solid formulation according to claim 121 in a capsule, wherein the said capsule contains 25 mg free base equivalent of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate.
- 125. (Amended) The desage form of claim 123 A dosage form consisting of the solid formulation according to claim 121 in a capsule, wherein the said capsule contains 50 mg free base equivalent of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide I-malate.
- 126. (Amended) The dosage form of claim 123 A dosage form consisting of the solid formulation according to claim 121 in a capsule, wherein the said capsule contains 100 mg free base equivalent of 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide L-malate.

127 to 130. (Canceled)